AcuityMD raises $80M to scale AI in MedTech, nearing $1B valuation
In an exclusive interview with MoveTheNeedle.news, Michael Monovoukas, CEO and co-founder of Boston-based AcuityMD, outlined how the company’s $80 million Series C funding round marks a defining step in its evolution from data platform to AI-driven intelligence layer for the medical technology (MedTech) sector.
The funding, announced in April 2026, was led by StepStone Group with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. The round values AcuityMD at $955 million and will fund the expansion of its artificial intelligence capabilities and underlying data platform.
From fragmented MedTech data to an AI platform
Founded in 2019 by Monovoukas alongside Robert Coe and Lee Smith, AcuityMD was built to address a persistent issue in MedTech: the lack of a unified, usable view of commercial data.
Across the medical device industry, large datasets—from regulatory filings and reimbursement data to procedure volumes—have long existed. But they remain fragmented, difficult to interpret, and rarely embedded into the workflows of commercial teams.
AcuityMD’s early product focused on aggregating and structuring this information, linking medical devices to physician activity and market dynamics. Over time, that foundation evolved into a more sophisticated data model mapping relationships between physicians, hospitals, procedures, and commercial behaviour.
That shift—from data aggregation to structured context—underpins the company’s current move into artificial intelligence.
Turning healthcare data into commercial intelligence
At the centre of the platform is what AcuityMD describes as a proprietary “MedTech ontology”: a continuously updated knowledge graph that connects disparate healthcare datasets and aligns them with each customer’s internal systems.
The problem it addresses is not simply access to healthcare data, but usability. In MedTech, much of the available information is incomplete or lacks the context required for decision-making in the field.
As Monovoukas explains: “Most commercial data in MedTech is either incomplete, context-free, or structured for the wrong purpose.”
By connecting these fragmented signals—across physicians, facilities, and procedures—the platform aims to provide a real-time, actionable view of the market.
AcuityAI: embedding AI into MedTech workflows
The introduction of AcuityAI marks a shift from insight generation to decision support. Built on top of the company’s data platform, the system is designed to surface relevant information directly within the workflows of commercial teams.
For field sales representatives, this changes how preparation and execution happen. Tasks such as building call plans, analysing account potential, or identifying new opportunities—once spread across multiple systems—are consolidated into a single interface.
Monovoukas frames the change in terms of speed and accessibility: “Anything that used to require hours of research is now easily discoverable.”
The platform also reduces administrative overhead by enabling users to log interactions and update records through voice or text, reflecting the mobile nature of MedTech sales roles.
Competing platforms: data, CRM and a new AI layer
AcuityMD operates in a competitive landscape that spans enterprise software, healthcare data platforms, and emerging AI-driven tools.
Large incumbents such as IQVIA and Veeva Systems provide extensive datasets, analytics, and customer relationship management (CRM) systems across life sciences. These platforms are widely embedded within organisations but were designed as broad systems of record rather than specialised decision-support tools for MedTech field teams.
At the same time, healthcare commercial intelligence providers offer datasets on hospitals, physicians, and procedures, helping companies identify target markets and build sales pipelines.
AcuityMD’s positioning sits between these categories. Rather than focusing solely on data access or analytics, it emphasises context—interpreting data within the specific conditions of a user’s territory, product portfolio, and commercial objectives.
As Monovoukas puts it: “When a rep opens AcuityAI, the context is already there.”
This distinction—between providing data and delivering decision-ready insight—is becoming increasingly important as artificial intelligence reshapes enterprise software.
Growth, scale and the $34 billion pipeline
The company’s near-unicorn valuation reflects both growth and adoption. AcuityMD expanded its customer base from 300 to nearly 500 companies within a year and now supports 16 of the top 20 MedTech manufacturers.
The platform has also identified more than $34 billion in potential commercial opportunities for its customers. This figure represents mapped opportunity rather than realised revenue. The distinction is critical: AcuityMD provides visibility and prioritisation, while execution remains with commercial teams.
“That $34B… is the answer to ‘where should I be going that I’m not going today?,” says Monovoukas.
Investor backing signals confidence in AI for MedTech
The Series C round comes at a time when funding for software companies has become more selective. Against that backdrop, the size and composition of the round suggest strong investor confidence in AcuityMD’s approach to AI in MedTech.
For Monovoukas, that support reflects alignment on long-term transformation rather than short-term performance: “Closing a round of this size required investors who genuinely believe the AI transformation of MedTech is real.”
Beyond sales: extending into the MedTech lifecycle
While AcuityMD is currently focused on commercial teams, its underlying data platform creates potential applications across the broader MedTech lifecycle.
Insights generated in the field—often captured inconsistently—could be structured and used to inform marketing, product development, and research and development (R&D). Over time, this could shift the platform from identifying opportunities to shaping how new medical technologies are developed.
“It starts with the field… and eventually helps teams understand which unmet needs are real,” says Monovoukas.
A defining moment for AI in MedTech
With a valuation approaching $1 billion, AcuityMD enters a new phase. Its challenge now is to translate its data and AI capabilities into consistent, scalable impact across a growing customer base.
The company’s core proposition remains unchanged: connecting fragmented healthcare data and turning it into actionable commercial intelligence. What has changed is how that intelligence is delivered—embedded directly into workflows and decisions.
As artificial intelligence becomes more deeply integrated into healthcare industries, platforms that combine data, context, and execution will define the next phase of competition in MedTech.
Liked this article? You can support our independent journalism via our page on Buy Me a Coffee. It helps keep MoveTheNeedle.news focused on depth, not clicks.